AI assistant
BeOne Medicines Ltd. — Director's Dealing 2019
Jun 7, 2019
30073_dirs_2019-06-07_feb5de1b-4d84-4ef2-9cb3-f2804ac54f1e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2019-06-05
Reporting Person: Huang Jane (CMO, Hematology)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-06-05 | Ordinary Shares | A | 62842 | — | Acquired | 334463 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-06-05 | Share Option (Right to Buy) | $9.23 | A | 462579 | Acquired | 2029-06-04 | Ordinary Shares (462579.0) | Direct |
Footnotes
F1: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.
F2: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.
F3: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.